Samsung Bioepis Report Flags Supply Reliability as Key US Biosimilar Market Factor

• Samsung Bioepis released its fourth-quarter 2026 US biosimilar market report, highlighting supply reliability as a purchasing consideration rivaling price.
• Up to a quarter or more of a wholesaler's biosimilar portfolio faced shortages or supply restrictions on a given day.
• Within five years of launch, biosimilars across key therapeutic classes averaged 55% market share, with average sales prices down 54%.
• Bevacizumab and ranibizumab biosimilars sustained recovered average sales prices across the third and fourth quarters, bucking historical price erosion.
• As of September 2026, the US had approved 98 biosimilars, with 75 launched, representing 77% of approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung EPIS Holdings Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220800BIZWIRE_USPR_____20261022_BW060999) on October 22, 2026, and is solely responsible for the information contained therein.